PHARMACOTHERAPY: Disparate bedfellows in a lasting drug union?

    loading  Checking for direct PDF access through Ovid

Abstract

Finan and colleagues report a new approach to combination therapy for the metabolic syndrome—glucagon-like peptide 1 and oestradiol linked chemically to produce a fusion molecule. Treatment with this fusion molecule results in an improvement of the metabolic profile of mice with diet-induced obesity with a minimum of oestrogenic adverse effects.

Related Topics

    loading  Loading Related Articles